Texas Life Science Forum: 4M Therapeutics is aiming make therapies for the CNS that are safer and more tolerable than current treatments

blonca9
Nov 7, 2024
1 min read

CEO Pablo Lapeurta, previously CMO of Lexicon, describes the lead programs for biopolar disorder and Alzheimer's agitation. Plus, Houston as a biotech hub for therapeutics areas beyond oncology, like neuroscience.

Brought to you by

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

Texas Life Science Forum: 4M Therapeutics is aiming make therapies for the CNS that are safer and more tolerable than current treatments

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight